SCHEMBL6946833

SCHEMBL6946833

Cc1ccc(Oc2ccc3c(c2)OCO3)nc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
MAPK1 P28482 1/20 0.47
NOS2 P35228 9/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
KCNH2 Q12809 1/20 0.41
GHSR Q92847 1/20 0.41
PIK3CD O00329 1/20 0.40
MAPT P10636 3/20 0.39
MAOB P27338 1/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941680 0.80 RAB9A (0.47) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL6942061 0.78 MAPK8 (0.50) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL108699 0.77 NOS2 (0.66) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL6941353 0.77 NOS2 (0.56) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL6947314 0.77 NOS2 (0.41) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL6939923 0.77 MEN1 (0.45) ALDH1A1NOS2NPC1RAB9ASMN1; SMN2
SCHEMBL6944274 0.76 MAPK8 (0.44) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL4610463 0.76 ALDH1A1 (0.44) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL6945757 0.75 MAPK8 (0.48) ALDH1A1MAPK1NOS2NPC1RAB9A
SCHEMBL6945487 0.74 MAPK1 (0.49) ALDH1A1MAPK1NOS2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 ALDH1A1 573/4885MAPK1 1452/4885NOS2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.